Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 2, 2016, Pages 242-250.e2

  Wils, Pauline ^a   Bouhnik, Yoram ^b   Michetti, Pierre ^c   Flourie, Bernard ^d   Brixi, Hedia ^e   Bourrier, Anne ^f   Allez, Matthieu ^g   Duclos, Bernard ^h   Grimaud, Jean Charles ⁱ   Buisson, Anthony ^j   Amiot, Aurélien ^k   Fumery, Mathurin ^l   Roblin, Xavier ^m   Peyrin Biroulet, Laurent ⁿ   Filippi, Jérôme ^o   Bouguen, Guillaume ^p   Abitbol, Vered ^q   Coffin, Benoit ^r   Simon, Marion ^s   Laharie, David ^t   Pariente, Benjamin ^a,u   more..

^a UNIV LILLE   (France)

^b BEAUJON HOSPITAL   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h HÔPITAL DE HAUTEPIERRE   (France)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^k University of Paris Est Créteil   (France)

^l AMIENS UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

ⁿ UNIVERSITY HOSPITAL OF NANCY   (France)

^o UNIVERSITY HOSPITAL OF NICE   (France)

^p RENNES UNIVERSITY HOSPITAL   (France)

^q Institut Cochin   (France)

^r HÔPITAL LOUIS MOURIER   (France)

^s INSTITUT MUTUALISTE MONTSOURIS   (France)

^t UNIVERSITÉ DE BORDEAUX   (France)

^u UNIVERSITÉ DE LILLE   (France)

more..

Author keywords

IL12; IL23; Immunosuppressant; Inflammatory Bowel Disease

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; MYCOPHENOLATE MOFETIL; PLACEBO; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; USTEKINUMAB; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ADULT; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; BRONCHITIS; COHORT ANALYSIS; CROHN DISEASE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EDEMA; EXTERNAL OTITIS; FEMALE; FOLLICULITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; RASH; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SINUSITIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; ADVERSE EFFECTS; EUROPE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; CROHN DISEASE; EUROPE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; USTEKINUMAB;

EID: 84958932029     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.09.018     Document Type: Article

References (26)

1. Pearson D.C., May G.R., Fick G.H., et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 123:132-142.
2. Feagan B.G., Fedorak R.N., Irvine E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000, 342:1627-1632.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Colombel J.-F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
5. Peyrin-Biroulet L., Cieza A., Sandborn W.J., et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis 2010, 16:15-22.
6. Pariente B., Mary J.-Y., Danese S., et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology 2015, 148:52-63.e3.
7. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
8. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333. quiz 591.
9. Gisbert J.P., Marín A.C., McNicholl A.G., et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015, 41:613-623.
10. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
11. Caspersen S., Elkjaer M., Riis L., et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol Off Clin Pract 2008, 6:1212-1217. quiz 1176.
12. Sands B.E., Feagan B.G., Rutgeerts P., et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014, 147:618-627.e3.
13. Sandborn W.J., Gasink C., Gao L.-L., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012, 367:1519-1528.
14. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5A-36A.
15. Sandborn W.J., Feagan B.G., Fedorak R.N., et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
16. Kopylov U., Afif W., Cohen A., et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-the McGill experience. J Crohns Colitis 2014, 8:1516-1522.
17. Lebwohl M., Yeilding N., Szapary P., et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010, 63:571-579.
18. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
19. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468. quiz e10-1.
20. Colombel J.-F., Reinisch W., Mantzaris G.J., et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther 2015, 41:734-746.
21. Tillack C., Ehmann L.M., Friedrich M., et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014, 63:567-577.
22. Hay R a.S, Pan J.Y. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol 2014, 39:751-752.
23. Caca-Biljanovska N., V'lckova-Laskoska M., Laskoski D. Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation. Acta Dermatovenerol Croat ADC 2013, 21:202-204.
24. Wenk K.S., Claros J.M., Ehrlich A. Flare of pustular psoriasis after initiating ustekinumab therapy. J Dermatol Treat 2012, 23:212-214.
25. Toussirot E., Michel F., Béreau M., et al. Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. Patient Prefer Adherence 2013, 7:369-377.
26. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.